LRRK2 G2019S Mutations are associated with an increased cancer risk in Parkinson Disease

Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may non-specifically inhibi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Saunders-Pullman, R, Barrett, MJ, Stanley, K, San Luciano, M, Shanker, V, Severt, L, Hunt, A, Raymond, D, Ozelius, LJ, Bressman, SB
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978749/
https://ncbi.nlm.nih.gov/pubmed/20818610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.23314
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller